✨ Free AI Report
Neos Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Neos Therapeutics, Inc.
Company Research

Neos Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD t...

Analyst-debate audio for Neos Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Neos Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
4/ 10Mixed

Cyborg Score thesis

Niche ADHD pharma play with established products but constrained by micro-cap valuation and thin pipeline...

Read the full analyst-debate transcript →
Industry Pharmaceuticals
4 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Neos Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Neos Therapeutics, Inc. Overview

Pro stress-test →

Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD treatment, plus generic Tussionex for cough and cold symptoms. As of May 24, 2026, the market cap is $57.23M.

Strategic Profile

Pro stress-test →

The company generated $62.5 million in annual revenue in 2026, positioning it as a specialized ADHD-focused pharmaceutical company. Neos is advancing clinical-stage pipeline with NT0502 for the treatment of sialorrhea in patients with neurological conditions, though its core business remains ADHD products and generic cough/cold formulations.

Competitive Landscape

Pro stress-test →

Top competitors include Cingulate, SciNeuro and STALICLA. Neos competes in the ADHD treatment space with branded and extended-release formulations, though its scale is significantly smaller than larger pharma players. The company also competes in generic cough/cold markets with Tussionex, a more commoditized segment.

Industry Context

Neos Therapeutics, Inc. operates in Pharmaceuticals.

Key facts

Founded: 2008 · Headquarters: Grand Prairie, Texas, US · Employees: 15 · Revenue: $62.5M (2026) · Market cap: $57.23M (as of May 2026)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Neos Therapeutics, Inc..

  • Generated $62.5M revenue in 2026 with only 15 employees, indicating operational efficiency but potential capacity constraints for scaling or pipeline advancement.
  • Market cap of $57.23M as of May 2026 sits below trailing revenue, reflecting investor skepticism about growth prospects or profitability trajectory despite established product commercialization.
+1 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • May 2026Market cap assessed at $57.23M
  • February 2026Pipeline data updated, NT0502 clinical trial status confirmed
  • +1 moreTrack every material event for Neos Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Neos Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Cingulate Inc.ADHD treatment competitor→Adlon TherapeuticsADHD treatment developer→Aytu BioPharmaExtended-release ADHD medications including Cotempla XR-ODT competitor→NaurexCNS disorder and ADHD treatment developer→

Compare Neos Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Neos Therapeutics, Inc. operates in Pharmaceuticals. See how the rest of the sector scores on the Cyborg framework.

Browse Pharmaceuticals research →
NEW · MCP server

Ask your AI assistant about Neos Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Neos Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Neos Therapeutics, Inc. do this quarter?”
“Is Neos Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Neos Therapeutics, Inc. do?+
Neos Therapeutics develops extended-release drugs for CNS disorders using proprietary technology platform. The company manufactures and markets Adzenys XR-ODT amphetamine and Cotempla XR-ODT methylphenidate for ADHD t...
What is Neos Therapeutics, Inc.'s Cyborg Score?+
Neos Therapeutics, Inc. has a Cyborg Score of 4/10 (Mixed). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Neos Therapeutics, Inc.'s main competitors?+
Named competitors include Cingulate Inc., Adlon Therapeutics, Aytu BioPharma, Naurex. The full competitive landscape is in the AskCyborg report.
How can I get the full Neos Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Neos Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Neos Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Pharmaceuticals research

Companies in the same sector and named competitors, ranked by Cyborg Score.

7Novartis AG7Recordati Industria Chimica e Farmaceutica SpA6CSPC Innovation Pharmaceutical Co., Ltd.8Cingulate Inc.